Free Trial
NASDAQ:LNSR

LENSAR (LNSR) Stock Price, News & Analysis

LENSAR logo
$13.91 +0.02 (+0.14%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$13.92 +0.00 (+0.04%)
As of 04/25/2025 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About LENSAR Stock (NASDAQ:LNSR)

Key Stats

Today's Range
$13.86
$13.98
50-Day Range
$9.29
$16.87
52-Week Range
$2.95
$17.31
Volume
170,669 shs
Average Volume
71,218 shs
Market Capitalization
$163.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Hold

Company Overview

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

LNSR MarketRank™: 

LENSAR scored higher than 24% of companies evaluated by MarketBeat, and ranked 829th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LENSAR has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LENSAR has only been the subject of 2 research reports in the past 90 days.

  • Read more about LENSAR's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LENSAR is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LENSAR is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LENSAR has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LENSAR's valuation and earnings.
  • Percentage of Shares Shorted

    1.19% of the float of LENSAR has been sold short.
  • Short Interest Ratio / Days to Cover

    LENSAR has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in LENSAR has recently decreased by 21.93%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    LENSAR does not currently pay a dividend.

  • Dividend Growth

    LENSAR does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.19% of the float of LENSAR has been sold short.
  • Short Interest Ratio / Days to Cover

    LENSAR has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in LENSAR has recently decreased by 21.93%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    LENSAR has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for LENSAR this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for LNSR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LENSAR insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    38.52% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LENSAR's insider trading history.
Receive LNSR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter.

LNSR Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Lensar downgraded to Hold from Buy at Lake Street
Lake Street Downgrades LENSAR (LNSR)
Lake Street Reaffirms Their Buy Rating on LENSAR (LNSR)
See More Headlines

LNSR Stock Analysis - Frequently Asked Questions

LENSAR's stock was trading at $8.94 at the beginning of 2025. Since then, LNSR stock has increased by 55.6% and is now trading at $13.91.
View the best growth stocks for 2025 here
.

LENSAR, Inc. (NASDAQ:LNSR) announced its earnings results on Thursday, February, 27th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.21) by $1.40. The company earned $16.73 million during the quarter, compared to analyst estimates of $14.95 million. LENSAR had a negative net margin of 34.03% and a negative trailing twelve-month return on equity of 49.02%.
Read the conference call transcript
.

Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), AstraZeneca (AZN), Baidu (BIDU), Cidara Therapeutics (CDTX) and The Carlyle Group (CG).

Company Calendar

Last Earnings
2/27/2025
Today
4/25/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LNSR
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+7.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,380,000.00
Pretax Margin
-34.03%

Debt

Sales & Book Value

Annual Sales
$53.49 million
Price / Cash Flow
N/A
Book Value
$2.97 per share
Price / Book
4.68

Miscellaneous

Free Float
7,141,000
Market Cap
$163.98 million
Optionable
Optionable
Beta
0.56
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:LNSR) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners